Gyre Therapeutics Strikes $300M All-Stock Deal to Acquire Cullgen, Bolstering TPD Pipeline for Cancer and Pain
Gyre Therapeutics agrees to acquire Cullgen in $300M all-stock deal, gaining TPD/DAC platform for oncology, pain, and inflammatory diseases. Deal to close Q2 2026 after Cullgen ends Pulmatrix merger.
